ADMA Biologics Inc
ADMAHealthcare|Biotechnology|USA
$9.11
-0.19 (-2.05%)
DCF (FCF)
$0.14
Tangible Book
$1.66
Graham Number
$4.99
Earnings Power
$0.22
Clinical Trials (7)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT03164967 Study to Evaluate Safety and Pharmacokinetics of BIVIGAM® in Primary Immune Deficiency Subjects Aged 2 to 16 | Humoral Immune Response | P4 | Completed | 16 | Open-label | Bivigam |
| NCT05070455 An Open Label, Multicenter Study to Evaluate the Pharmacokinetics, Efficacy and Safety of ASCENIV™ (IGIV) in Pediatric Subjects With Primary Immunodeficiency Diseases (PIDD) | Primary Immune Deficiency | P4 | Unknown | 12 | Open-label | Asceniv™ |
| NCT00538915 Open Label, Phase III Study of NABI-IGIV 10% [Immune Globulin Intravenous(Human), 10%] In Subjects With Primary Immune Deficiency Disorders (PIDD) | Primary Immune Deficiency Disorders (PIDD) | P3 | Completed | 63 | Open-label | Nabi-IGIV 10% [Immune Globulin Intravenous (Human). 10%] |
| NCT01814800 Pharmacokinetics, Efficacy, and Safety Study of RI-002 (IGIV) in Subjects With Primary Immunodeficiency Diseases (PIDD) | Primary Immune Deficiency Disorder | P3 | Completed | 59 | Open-label | RI-002 |
| NCT00473824 Randomized Phase II Study of Hepatitis C Immune Globulin Intravenous (Human), Civacir(TM), in Liver Transplantation | Sequelae of Viral Hepatitis, Transplantation Infection | P2 | Terminated | 7 | RCT, Open-label | Hepatitis C Immune Globulin Intravenous (Human) 5% |
| NCT00632463 RI-001 in Immunosuppressed Respiratory Syncytial Virus (RSV) Infected Patients at Risk of Lower Tract RSV Illness | Upper Respiratory Tract Infection, Lower Respiratory Tract Infection | P2 | Completed | 21 | RCT, Double-blind | RI-001, RI-001, RI-001 |
| NCT03037359 A Study About Low Blood Pressure in Patients With Primary Immunodeficiency Disease Treated With Immune Globulin Products | Primary Immune Deficiency Disorder | Unknown | 200 | — | Bivigam, Other |